Professor Thomas Zeller PI of the MIMICS-2 IDE study has announced that the freedom from CDTLR at 3 years for the BioMimics 3D stent was 81%, which is comparable to the outcomes for DCB, DES and Supera, despite treating more challenging lesions and without the need for lesion preparation.